scPharmaceuticals (NASDAQ:SCPH) Upgraded by Wall Street Zen to Hold Rating

Key Points

• scPharmaceuticals has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, indicating a shift in analyst sentiment regarding the stock.
• The company's recent quarterly earnings report revealed an EPS of ($0.34), missing expectations, but revenue reached $16.04 million, exceeding analyst estimates.
• Institutional investors have significantly increased their holdings in scPharmaceuticals, with 89.52% of the stock currently owned by them, reflecting growing confidence in the company's prospects.

Wall Street Zen upgraded shares of scPharmaceuticals (NASDAQ:SCPH - Free Report) from a sell rating to a hold rating in a research note released on Saturday morning.

scPharmaceuticals Stock Performance

NASDAQ SCPH traded down $0.38 during trading hours on Friday, hitting $4.63. The company had a trading volume of 846,492 shares, compared to its average volume of 338,919. scPharmaceuticals has a fifty-two week low of $1.94 and a fifty-two week high of $6.28. The company has a quick ratio of 3.14, a current ratio of 3.85 and a debt-to-equity ratio of 3.86. The business has a fifty day simple moving average of $4.46 and a 200-day simple moving average of $3.48. The firm has a market cap of $246.78 million, a P/E ratio of -2.56 and a beta of 0.40.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.04). scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%. The company had revenue of $16.04 million during the quarter, compared to analyst estimates of $15.41 million. Equities analysts predict that scPharmaceuticals will post -1.53 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Chicago Partners Investment Group LLC bought a new position in scPharmaceuticals during the first quarter valued at about $31,000. Assenagon Asset Management S.A. bought a new position in scPharmaceuticals during the first quarter valued at about $33,000. Police & Firemen s Retirement System of New Jersey boosted its stake in scPharmaceuticals by 63.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,336 shares of the company's stock valued at $36,000 after buying an additional 3,628 shares in the last quarter. Moss Adams Wealth Advisors LLC bought a new position in scPharmaceuticals during the second quarter valued at about $38,000. Finally, Legato Capital Management LLC boosted its stake in scPharmaceuticals by 48.1% during the first quarter. Legato Capital Management LLC now owns 15,275 shares of the company's stock valued at $40,000 after buying an additional 4,961 shares in the last quarter. Institutional investors own 89.52% of the company's stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.